Preparation and application of hybridoma cell

The OmpA monoclonal antibody of the intracellular Lawsonia outer membrane protein was prepared by cell fusion hybridoma technology, and WB, IFA and blocking ELISA detection methods were established, which solved the complex and long-term problems of diagnosis methods in the existing technology, and achieved rapid Accurate detection of hyperplasia in pigs reduces economic losses.

CN118909105AActive Publication Date: 2024-11-08HUAZHONG AGRI UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202410892378.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-04
Publication Date
2024-11-08
Estimated Expiration
2044-07-04

AI Technical Summary

Technical Problem

The existing diagnosis methods for pig hyperplasia ileitis have problems such as cumbersome detection of fecal samples and serological diagnosis that require two weeks to detect antibodies, resulting in serious economic losses in domestic pig farms and lack of fast and effective differential diagnosis methods for intracellular Lawsonia .

Method used

The OmpA-specific monoclonal antibody of the intracellular Rhossonian outer membrane protein was prepared by cell fusion hybridoma technology, and WB, IFA and blocking ELISA detection methods were established to develop commercial kits to achieve rapid detection.

Benefits of technology

It has been successfully applied to various immunologic tests, providing a fast and effective intracellular Lawsonia detection method, making up for the shortcomings of the existing technology, and improving diagnostic efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909105A_ABST
    Figure CN118909105A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of animal bacteriology and molecular biology, and relates to preparation and application of a hybridoma cell strain. A monoclonal antibody is prepared through the prokaryotically expressed outer membrane protein OmpA of the Lawsonia intracellularis, and immunological detection methods for detecting or diagnosing IFA, WB, blocking ELISA and the like of the Lawsonia intracellularis are established through the expressed outer membrane protein OmpA of the Lawsonia intracellularis and the prepared monoclonal antibody of the OmpA of the Lawsonia intracellularis. The blocking ELISA for detecting the Lawsonia intracellularis serum antibody can detect serum samples suspected to be infected by Lawsonia intracellularis from different species sources, does not have cross reaction with common pig pathogen positive serum, and is high in detection sensitivity and specificity, good in repeatability and suitable for high-throughput detection of the serum samples.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of animal bacteriology and molecular biology, and relates to the preparation and application of a hybridoma cell, and specifically to a monoclonal antibody specific to the outer membrane protein OmpA of Lawsonia intracellularis, and a preparation method and application thereof. Background Art

[0002] Lawsonia intracellularis (LI) mainly causes porcine proliferative enteropathy (PPE), with proliferative hemorrhagic enteropathy (PHE) and porcine intestinal adenomatosis (PIA) as typical symptoms. LI mainly infects weaned piglets and fattening pigs, presenting three clinical symptoms: acute, chronic and subclinical. The chronic type is the most common, and in severe cases, diarrhea and even death may occur. Porcine proliferative enteritis is one of the common diseases in intensive farms and is widely prevalent in major pig-raising countries around the world. In addition to occasionally causing acute deaths of medium and large pigs, the main hazard to the pig industry is that the widespread chronic infection of LI in pig populations has seriously affected the feed conversion rate, causing significant economic losses to the global breeding industry.

[0003] So far, six LI genome sequences have been deposited in the National Center for Biotechnology Information (NCBI) database, including the full genome sequences of two pathogenic isolates of swine origin. The complete genome of the LI strain includes a 1.4Mb chromosome and three plasmid genomes of 27, 39 and 194kb, containing 1324 ORFs. Molecular studies of intracellular Lawsonia isolates from various animal species, including horses and hamsters, showed 98% homology with the 16S-RNA of pig isolates. In addition, phenotypic characterization of the outer membrane proteins and immunoblotting of different intracellular Lawsonia showed only minor differences between the isolates, and the antigenic correlation was not affected. It was demonstrated that there was little or no genetic variation between the isolates of intracellular Lawsonia.

[0004] Among them, the outer membrane protein OmpA of intracellular Lawsonia spp. is composed of 340 amino acids. It is a hydrophilic protein with good immunogenicity and conservation. Although the molecular mechanism of the outer membrane protein OmpA in intracellular Lawsonia spp. has not been characterized, in many pathogenic bacteria, due to its high expression outside the membrane, OmpA-like proteins are involved in a variety of important pathogenic effects, including bacterial adhesion, invasion or intracellular survival, and escaping host defense or stimulating factors for the production of proinflammatory cytokines. These pathogenic effects are most often associated with diseases of the central nervous system, respiratory system, and urogenital system. Therefore, OmpA protein has also become one of the potential candidate antigens for subunit vaccines.

[0005] At present, the methods used to diagnose Lawsonia intracellularis infection at home and abroad are mainly serology and various PCR methods for detecting fecal samples. PCR is the most commonly used means of pathogen detection in laboratories and clinics. PCR is only suitable for the detection of fecal samples of infected animals during the bacterial excretion period. The steps for extracting the genome from feces are relatively cumbersome and not suitable for detecting large numbers of samples. Serological diagnosis mainly relies on enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence assay (IFA). These two methods not only have high sensitivity and specificity, but also the specific antibodies against Lawsonia intracellularis can exist in the body for a longer time. The disadvantage is that antibodies can only be detected at least two weeks after infection. In recent years, the economic losses caused by PPE in domestic pig farms have become increasingly serious. Therefore, there is an urgent need for differential diagnosis methods of Lawsonia intracellularis to conduct epidemiological surveys of Lawsonia intracellularis in my country's pig herds, evaluate the effectiveness of vaccine immunity, and evaluate the effectiveness of prevention, control and purification.

[0006] Since there is no commercial ELISA test kit in China for serological diagnosis, it is necessary to provide a mature ELISA test method to fill the gap in this field. The present invention prepares a monoclonal antibody specific for the outer membrane protein OmpA of intracellular Lawsonia intracellularis by cell fusion hybridoma technology, and establishes immunological detection methods such as WB, IFA and blocking ELISA. Summary of the invention

[0007] The present invention aims at solving the technical problem and overcomes the shortcomings of the prior art to provide a hybridoma cell preparation and application thereof, and specifically relates to a Lawsonia intracellularis outer membrane protein OmpA specific monoclonal antibody and its preparation method and application.

[0008] The invention discloses the preparation and application of a monoclonal antibody specific for the outer membrane protein OmpA of intracellular Lawsonia. The monoclonal antibody specific for the outer membrane protein OmpA of intracellular Lawsonia was prepared using cell fusion hybridoma technology, and the prepared monoclonal antibody specific for the outer membrane protein OmpA of intracellular Lawsonia was successfully applied to various immunological tests. A blocking ELISA detection method for detecting antibodies against the outer membrane protein OmpA of intracellular Lawsonia was established based on the prepared recombinant antigen and its monoclonal antibody, which can be used for the development of commercial kits.

[0009] One of the technical solutions of the present invention is to provide the preparation of monoclonal antibodies against the outer membrane protein OmpA of intracellular Lawsonia spp., wherein the monoclonal antibodies against the outer membrane protein OmpA of intracellular Lawsonia spp. are produced by hybridoma cell line 5F2, and the cell line is named hybridoma cell line 5F2, and the hybridoma cell line 5F2 was submitted to Wuhan University, China for preservation on September 15, 2023; the preservation number is CCTCC NO: C2023263.

[0010] The Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody of the present invention can be used for immunological detection of the Lawsonia intracellularis outer membrane protein OmpA.

[0011] Furthermore, the Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody can be used for detecting the Lawsonia intracellularis outer membrane protein OmpA in ELISA, WB or IFA experiments.

[0012] The second technical solution of the present invention is to provide an antibody preparation, which comprises the above-mentioned Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody, or the antibody preparation comprises a fragment of the monoclonal antibody.

[0013] The antibody preparation is further used for effectively diagnosing or detecting Lawsonia intracellularis.

[0014] The third technical solution of the present invention is to provide the use of the monoclonal antibody against the outer membrane protein OmpA of intracellular Lawsonia spp. in blocking ELISA for detecting intracellular Lawsonia spp.

[0015] The present invention also provides the use of the above-mentioned Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody and antibody preparation in the preparation of diagnosis or detection of Lawsonia intracellularis.

[0016] The present invention prepares two monoclonal antibodies against the outer membrane protein OmpA of Lawsonia intracellularis through prokaryotic expression. The two monoclonal antibodies against the outer membrane protein OmpA of Lawsonia intracellularis can be used for a variety of immunological tests, including ELISA, WB and IFA, and have a wide range of uses. At the same time, based on the prepared recombinant antigen and one of the monoclonal antibodies, a blocking ELISA method that can be used to detect Lawsonia intracellularis is explored and optimized, and the compliance rate is higher than that of existing commercial kits.

[0017] The monoclonal antibody specific for the outer membrane protein OmpA of intracellular Lawsonia is a useful tool for studying intracellular Lawsonia, and has been successfully applied to various immunological tests, including enzyme-linked immunosorbent assay (ELISA), western blot (WB) and immunofluorescence (IFA) experiments. At the same time, the invention establishes a blocking ELISA method for detecting intracellular Lawsonia, which provides a new reference for the detection of intracellular Lawsonia.

[0018] Description of preservation certificate and survival information

[0019] Deposited strain: The classification name of hybridoma cell line 5F2 is Hybridoma cell line 5F2, the deposit number is CCTCCNO: C2023263, the deposit date is September 15, 2023, the depositor is China Center for Type Culture Collection, and the deposit address is Wuhan University, Wuhan, China. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 This is a construction diagram of the pET30a-ompA plasmid of the present invention.

[0021] Figure 2 This is the identification diagram of the target fragment of ompA amplified by PCR in the present invention

[0022] Figure 3 This is the double enzyme digestion identification diagram of the pET30a-ompA plasmid of the present invention

[0023] Figure 4 This is a schematic diagram of the results of SDS-PAGE Coomassie Brilliant Blue staining identification of the recombinant purified LI OmpA protein in the present invention.

[0024] Figure 5 This is a schematic diagram of the Western blotting identification results of the recombinant purified LI OmpA protein in the present invention.

[0025] Figure 6 This is a schematic diagram of the Western blotting identification results of the LI OmpA monoclonal antibody 5F2 clone in the present invention.

[0026] Figure 7 Schematic diagram of Western blotting identification results of LI OmpA monoclonal antibody 12F6 clone in the present invention.

[0027] Figure 8 It is a schematic diagram of the IFA detection results of the 5F2 monoclonal antibody in the present invention.

[0028] Fig. 9 It is a schematic diagram of the IFA detection results of the 12F6 monoclonal antibody in the present invention.

[0029] Fig.10 It is a schematic diagram of the detection results of 5F2 and 12F6 monoclonal antibody subclasses in the present invention.

[0030] Fig.11 The figure is a schematic diagram of the SDS-PAGE Coomassie Brilliant Blue staining identification results of the purified 5F2 ascites monoclonal antibody in the present invention.

[0031] Fig.12 It is a schematic diagram of ROC curve analysis of the blocking ELISA detection results in the present invention. DETAILED DESCRIPTION

[0032] The present invention will be further described below in conjunction with specific embodiments, and the advantages and features of the present invention will become clearer as the description proceeds. However, it should be understood that the embodiments are exemplary only and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications or replacements all fall within the protection scope of the present invention.

[0033] Description of the sequence listing:

[0034] (1) SEQ ID NO: 1 is the nucleotide sequence of ompA in the pET30a-ompA recombinant plasmid in Example 1 of the present invention. The specific sequence is as follows.

[0035] Atgaaaattatccattctgcaatttttgctgttacattattaacagcatggtcaacagtttgctttgctgcagaagttac

[0036] agctagttgtactaaacgtgttgaaagctataattatcttgtggattattcaggctctatgatgatgaaacatgttgctg

[0037] ttagagagcctaaaatagaattagcaaaagaagctatattaaaaattaatgcggcaatgcctaaaatgtcatatcaaggt

[0038] ggattatatacttttgcaccttattctgtaattattccccaaggttcttggaattcatgtgttgccgaatgtgcggttaa

[0039] tacaattaagtctgatttagaaatttttggtcgtcttactcctatggggagacggcataaaaatgcatgaaacagtcatta

[0040] atcaaatgccccctcaggcagccgttattcttctcactgatggtcataataatttagggatgaatcctgttgaggaagta

[0041] aaatctatatatcaaacaaatcctaatgtttgttttcatgtagtttcatttgcagatgatgctgaaggcaaagcaataat

[0042] tgatcaaattgttgcacttaatagtggaagtgttcttgttgatggtttacagcttctacaaaatcctgctgtttgccaag

[0043] aatttgttaatagtgttttttgtcaagagcaaattcttgttacagaagaagttgttgtacttcgtggtgtaaactttgct

[0044] tttgattcttttgcattagatgatactgctaaagctattttagaagaaacagttcgtcttatcagagcaaatccagattt

[0045] taatgttcgtttgcttgggtggacagatagtactggtcctgatgcatataacttgcgtttatcacaagaacgtgctgatg

[0046] cagttaaaaacttcttggttaaaatgggtataccttcaaatcgtttatttgctaaaggaatgggtaaatcctatcagtat

[0047] aataatgctacaaaagaaggacgatatatgaatcgtcgtacagaacttgtcttttttgattag

[0048] (2) SEQ ID NO: 2 is the specific amino acid sequence list of ompA in the pET30a-ompA recombinant plasmid in Example 1 of the present invention, and the specific sequence is as follows.

[0049] MKIIHSAIFAVTLLTAWSTVCFAAEVTASCTKRVESYNYLVDYSGSMMMKHVAVREPKIELAKEAILKINAAMPKMSYQG

[0050] GLYTFAPYSVIIPQGSWNSCVAECAVNTIKSDLEIFGRLTPMGDGIKMHETVINQMPPQAAVILLTDGHNNLGMNPVEEV

[0051] KSIYQTNPNVCFHVVSFADDAEGKAIIDQIVALNSGSVLVDGLQLLQNPAVCQEFVNSVFCQEQILVTEEVVVLRGVNFA

[0052] FDSFALDDTAKAILEETVRLIRANPDFNVRLLGWTDSTGPDAYNLLRLSQERADAVKNFLVKMGIPSNRLFAKGMGKSYQY

[0053] NNATKEGRYMNRRTELVFFD

[0054] Example 1 Cloning and expression of LI OmpA gene, protein purification and preparation of monoclonal antibodies

[0055] 1.1 Screening and preparation of strains, plasmids, cells and experimental animals

[0056] The pET30a-ompA plasmid was preserved in this laboratory (a plasmid prepared by conventional experimental methods) and was used to express the OmpA recombinant protein; myeloma cells SP2 / 0 stored in the laboratory were revived; and BALB / c mice were purchased from Henan Sikebes Biotechnology Co., Ltd. for cell fusion.

[0057] The coding nucleotide sequence of the ompA gene is shown in the sequence listing SEQ ID NO: 1.

[0058] 1.2 Main experimental reagents and consumables

[0059] SDS-PAGE kit was purchased from Yazyme; RPMI Medium 1640basic (1x) was purchased from Gibco; Freund's complete adjuvant (FCA), Freund's incomplete adjuvant (FIA), PEG 50, HAT Media Supplement, HT Media Supplement, and DMSO were purchased from Sigma; FBS serum was purchased from Yeasen; TMB two-component colorimetric solution and stop solution were purchased from Solebol; HRP-labeled goat anti-mouse IgG antibody, BCA protein quantification kit, and BeyoGold TMHis-tag Purification Resin (reduction-resistant chelating type) was purchased from Biyuntian Company; Tween-20 was purchased from Nanjing Yifeixue Biotechnology Company; LB solid powder was purchased from Oxoid Company; IPTG, ampicillin, and NAD coenzyme powder were purchased from Biosharp Company; monoclonal antibody subtype identification kit was purchased from Proteintech Company; cell culture plates were purchased from Biofil Company; other chemical reagents were commercially available reagents. The reagents were prepared on-site by the laboratories of the College of Animal Science and Technology and the College of Veterinary Medicine where the applicant is located, and the purity was analytically pure.

[0060] 1.3 Construction of LI-ompA prokaryotic expression plasmid

[0061] 1.3.1 Cloning of LI ompA gene

[0062] Un-signal peptide and transmembrane region ompA (uompA) were designed based on the bioinformatics prediction results of LI ompA, and the recombinant plasmid map was constructed using snapGene 3.2.1 (see Figure 1 ) and designed upstream and downstream primers: uompA-F, uompA-R, (the primers contain restriction sites BamH-Ⅰ and Not-Ⅰ, see Table 1 for details), the primers were synthesized by Wuhan Qingke Biotechnology Co., Ltd. See Table 1 and Table 2:

[0063] Table 1 Primer information for amplifying ompA gene

[0064]

[0065] The target gene was synthesized using porcine LI attenuated vaccine DNA as a template. The reaction system is shown in Table 2.

[0066] Table 2 PCR reaction system for amplifying ompA gene

[0067]

[0068] According to the above reaction system, the target fragment was amplified by the reaction program of 98°C pre-denaturation for 3 min, 98°C denaturation for 15 s, 50°C annealing for 15 s, 72°C extension for 15 s, 30 cycles, and 72°C extension for 3 min. The amplified fragment size was 1023 bp (see Figure 2 ).

[0069] 1.3.2 Construction of recombinant plasmid pET30a-ompA

[0070] When the 1% agarose gel was positive, the ompA fragment was recovered by cutting the gel. The reaction sample was added with 5× Loading Buffer and mixed. After 1% agarose gel electrophoresis, the target band was cut and the target gene was recovered and purified according to the instructions of the DNA purification and recovery kit. Using pET30a as the vector, BamH-Ⅰ and Not-Ⅰ were digested and connected to pET30a and the above PCR amplification product to construct the recombinant plasmid pET30a-ompA. The double enzyme digestion identification results showed that the recombinant plasmid was successfully constructed (see Figure 3 ).

[0071] 1.4 Expression and purification of Lawsonia intracellularis OmpA recombinant protein

[0072] First, the E. coli containing the pET30a-OmpA recombinant plasmid stored in the ultra-low temperature freezer was revived, and 100 μL of the bacteria was evenly spread on the Kana resistance plate and cultured at 37°C overnight. A single colony was picked and placed in 700 μL of LB liquid culture medium with Kana resistance and shaken at 37°C for about 8-12 hours. 100 μL of the above bacterial liquid was inoculated into 10 ml of LB liquid culture medium with Kana resistance and shaken at 37°C for about 8-12 hours to obtain the revived recombinant expression bacteria. The revived strain was inoculated into 1L of LB liquid culture medium with Kana resistance and shaken at 37°C until the OD 450nm The value was changed to 0.6-0.8. After induction with 0.8mmol / L IPTG at 25℃ for 16h, OmpA recombinant protein was expressed. The purified recombinant antigen was obtained by His tag affinity chromatography; the purified recombinant antigen was analyzed by SDS-PAGE (see Figure 4 ) and Western-Blot (see Figure 5 ) Verify the correctness and immunogenicity of the recombinant protein. After the correct recombinant protein is dialyzed and concentrated, the protein concentration is determined using the BCA method and the protein is dispensed into 1.5 ml Eppendorf tubes and stored at -80°C for later use.

[0073] 1.5 Immunization of mice

[0074] The immunization antigen was the prepared LI OmpA protein, and the immunization procedure was as follows: 200 μg of recombinant protein was emulsified with Freund's complete adjuvant at a ratio of 1:1 and then injected intraperitoneally into Balb / C mice for immunization. On days 14 and 28, the same dose of recombinant protein was emulsified with Freund's incomplete adjuvant at a ratio of 1:1 for the second and third immunizations. Blood was collected 7 days after the third immunization to detect the serum antibody titer. When the mouse serum antibody titer reached 1:12800, the mouse with the highest antibody titer was selected for shock immunization, and cell fusion was performed 3 days after the shock immunization.

[0075] 1.6 Indirect ELISA method antibody detection

[0076] 1.6.1 Preparation of serum to be tested

[0077] The blood of 5 mice was collected from the tail tip, incubated in a 37℃ incubator for 30 minutes, transferred to a 4℃ refrigerator and left to stand overnight, centrifuged at 4000r / min for 5 minutes, and the upper liquid was aspirated as the serum to be tested. If there is any residue after the test, it can be stored in a -80℃ refrigerator.

[0078] 1.6.2 Preparation of antigen-coated plates and determination of serum titer

[0079] The concentration of LI OmpA protein was adjusted to 1 μg / mL using 0.05 mol / L carbonate buffer (pH 9.6). 100 μL of antigen coating solution was added to each ELISA test well using a spray gun. The plate was placed in a 4°C refrigerator overnight. The liquid in the plate was discarded. 300 μL of PBST was added to each well for washing 5 times and patted dry. Subsequently, 100 μL of 2% BSA was added to each well for blocking. The plate was placed in a 37°C incubator for 2 hours, and the blocking solution was discarded. The plate was washed with PBST in the same manner and patted dry. For titer detection, 200 μL of immune positive mouse serum and non-immunized mouse serum diluted 1:100 were added to the first well of each row, and 100 μL of PBST was added to each of the remaining wells. 100 μL of the mixed liquid was drawn from the first well and added to the second well. The dilution was repeated until the 6th well was discarded and 100 μL was placed in the incubator for incubation. After 1 hour, discard the liquid wash plate, add HRP-labeled goat anti-mouse IgG antibody, dilute it with PBST at a dilution of 1:5000 and add it to the wells. After incubation in the incubator for 1 hour, wash and pat dry, add 100 μL TMB to the enzyme-labeled wells for color development, and develop in the incubator in the dark for 10 minutes. The enzyme reader is adjusted to OD 450nm Prepare for reading. After color development, add 50 μL of 2M sulfuric acid stop solution and read. When the P / N value is ≥2.1 and the OD 450nm >0.4 is positive, and the highest dilution of serum when it is judged positive is the serum antibody titer.

[0080] 1.7 Cell fusion

[0081] 1.7.1 Preparation of materials, instruments, equipment and reagents

[0082] Materials: 96-well cell plate, sterile 50mL centrifuge tube, sterile 15mL centrifuge tube, sterile filter paper, sterile grinder, sterile rodenticide, sterile 10mL pipette; 40μm cell sieve, cell counting plate, dissection plate and fixing needle, alcohol cotton ball.

[0083] Instruments and equipment: water bath, centrifuge, balance, 37℃ constant temperature box.

[0084] Reagents: 75% ethanol, 100 mL RPMI 1640 medium (containing 1% double antibody), 100 mL HAT medium (1% double antibody, 2% HAT, 20% newborn fetal bovine serum, RPMI 1640 supplemented to 100 mL).

[0085] 1.7.2 Preparation of feeder cells

[0086] One day before fusion, mature and healthy Balb / C mice were taken, killed by cervical dislocation, and then immersed in 75% ethanol for 5 minutes and placed in a sterilized glass dish on a clean bench. After the dissection board was disinfected with 75% ethanol, it was fixed on the board. Under sterile conditions, it was cut along the midline of the abdomen, and the skin and peritoneum were bluntly separated to fully expose the abdomen. An appropriate amount of HAT was drawn with a sterile syringe and injected into the mouse abdominal cavity (be careful to avoid penetrating tissues and internal organs). After gently kneading the mouse abdomen, the culture fluid that had been flushed with the abdomen was aspirated. After repeating this step twice, the abdominal cavity was opened aseptically to remove the spleen, and placed in a grinder containing 5 mL of serum-free RPMI 1640 culture medium. The matched grinding rod was used to slowly grind 6-8 times, 5 mL of serum-free RPMI 1640 culture medium was added and allowed to stand for 3 minutes, 5 mL of the upper cell suspension was drawn into a 50 mL centrifuge tube, and the above operation was repeated 2-3 times. After the spleen cells were fully released, the lower cell suspension was filtered with a 40 μm cell sieve, and the filtrate was transferred to a 50 mL centrifuge tube. Finally, 30 mL of serum-free RPMI 1640 was added, and centrifuged at 1000 r / min for 10 minutes. The supernatant was discarded and 10 mL Resuspend the precipitate with HAT, add 60 mL of HAT, mix thoroughly, add to a 96-well cell culture plate, 100 μL / well, and place in a 37°C, 5% CO2 incubator overnight. Observe the bottom of the cell plate the next day. If it is clear and transparent without turbidity, cell fusion can be performed; if contamination occurs, prepare feeder cells again according to the above steps.

[0087] 1.7.3 Collection of myeloma cells (SP2 / 0)

[0088] SP2 / 0 cells were revived two weeks before fusion. The medium was changed every day according to the cell growth and subcultured every two days to ensure that the cell count before fusion exceeded 2×10 7 When preparing for fusion, select SP2 / 0 cells with good morphology and logarithmic growth, wash with serum-free RPMI 1640 and blow off, transfer to a 50mL centrifuge tube sterilized in advance, and finally add 30mL of serum-free RPMI 1640, 1000r / 10min, discard the supernatant, resuspend the precipitate with 10mL of serum-free RPMI 1640, and place in a 37°C beaker in a water bath for later use.

[0089] 1.7.4 Collection of immune spleen cells

[0090] On the third day after booster immunization, blood was collected from the eyeballs of the immunized mice and the serum was separated as an antibody positive control, which was packaged and stored in a -80°C refrigerator. Mice killed by cervical dislocation were soaked in 75% alcohol for 5 minutes, with the abdomen facing upwards, and the limbs were fixed on a sterilized mouse killing board with pins. The abdominal cavity was opened aseptically to remove the spleen, and placed in a grinder containing 5 mL of serum-free RPMI 1640 medium. The spleen was slowly ground 6-8 times using the matching grinding rod, and 5 mL of serum-free RPMI 1640 medium was added and allowed to stand for 3 minutes. 5 mL of the upper cell suspension was aspirated into a 50 mL centrifuge tube, and the above operation was repeated 2-3 times to fully release the spleen cells. After that, the lower cell suspension was filtered with a 40 μm cell sieve, and the filtrate was transferred to a 50 mL centrifuge tube. Finally, 30 mL of serum-free RPMI 1640 was added, and the mixture was incubated at 1000 r / 10 min. The supernatant was discarded, and the precipitate was resuspended with 10 mL of serum-free RPMI 1640 and placed in a beaker at 37°C in a water bath for later use.

[0091] 1.7.5 Cell fusion method

[0092] (1) Preheat HAT and RPMI 1640 culture medium 30 minutes in advance; pipette the prepared spleen cell and SP2 / 0 cell suspensions respectively, add them to 50 mL centrifuge tubes, and gently mix. Make up the suspension volume to 30 mL with serum-free RPMI 1640, centrifuge at 1000 r / min for 10 minutes, and discard the supernatant as much as possible. Gently tap the bottom of the tube with your fingers, and gently tap the bottom on the edge of the clean bench to loosen the precipitated cells. Place the centrifuge tube in a beaker in a 37°C water bath for later use.

[0093] (2) Preheat a 1.5 mL centrifuge tube containing 1 mL of PEG50 in a 37°C water bath. Use a Pasteur pipette to draw 1 mL of PEG50 into the centrifuge tube, gently stirring while adding. The PEG50 should be added within 1 min on average. After adding, gently stir for 30 s to allow the PEG50 and cells to be fully mixed, and then let stand for 30 s. Then slowly add 10 mL of preheated serum-free RPMI 1640 within 5 min. Add one drop every 2 s in the first 30 s of the first minute, and one drop every 1 s in the last 30 s. Add 2 mL in the second minute and 3 mL in the third minute until 10 mL of 1640 culture medium is added. Let stand in a 37°C incubator for 10 min, centrifuge at 1000 r / min for 10 min, and discard the supernatant. Add an appropriate amount of HAT culture medium, pipette and resuspend the fused cells, and gently shake to mix the precipitated cells evenly before spreading on a plate. The next day, observe the plate for contamination. If contamination occurs, seal the well and the surrounding 8 wells with 1M NaOH.

[0094] (3) After the cell plate is placed in a 37°C, 5% CO2, saturated humidity incubator for 5 days, the cell growth status is observed under a microscope. The growth of cell clusters in each well is recorded in a timely manner. On the 6th to 8th day of fusion, half of the medium is replaced with HAT medium. On the 9th day, HT medium is used. The growth rate and status of the cell clusters in the wells are observed every day. When the size of the cell clusters occupies about 1 / 10 of the bottom of the well, the positive hybridoma cell clones can be screened for the first time.

[0095] 1.7.6 Screening and subcloning of antibody-secreting hybridoma cell clusters

[0096] The indirect ELISA method was used to screen the hybridoma cell clones that secreted antibodies. The 96-well plate was coated with purified LI OmpA protein, and the positive serum separated from the eyeball blood was diluted 1:100 as the positive control; the negative control was SP2 / 0 supernatant. The ELISA instrument was set to OD 450nm After reading, it can be judged as positive when P / N ≥ 2.1. Subclone the positive hybridoma at least three times by limiting dilution and test the supernatant. If there are many positive wells, select the wells with larger P / N values ​​and better cell growth conditions for the next subcloning operation.

[0097] The subcloning of the present invention is carried out by limiting dilution method. The preparation method of feeder cells the day before is shown in 1.6.2. When the size of the clone group in the well is about 1 / 4 to 1 / 2 of the whole well, it is the best time for subcloning. Generally, three subclonings are required to obtain a hybridoma cell line that stably secretes antibodies. After each subcloning, when the cell group grows to 1 / 4, the supernatant is aspirated for detection. The method is as described in 1.6.6 of this embodiment for screening and subcloning of hybridoma cell groups secreting antibodies. Each subcloning selects a positive well of a single cell group. The sign of the end of subcloning is that all subcloned cell groups are positive. A total of 2 monoclonal antibodies were prepared, named 5F2 and 12F6.

[0098] Example 2 Identification of monoclonal antibodies against LI OmpA protein

[0099] 1.1 Western blot specificity analysis of monoclonal antibodies

[0100] Take 80μL OmpA protein solution, add 20μL 5×SDS PAGE Loading Buffer and mix well, boil at 100℃ for 10min for later use. Perform 12.5% ​​SDS PAGE gel electrophoresis with a loading volume of 20μg / well; after transferring to PVDF membrane, place the PVDF membrane in 5% skim milk (prepared with PBST) and incubate at 4℃ overnight. Dilute the hybridoma cell supernatant 10 times with PBST and incubate with the PVDF membrane at room temperature for 2h. Add 1:5000 diluted secondary antibody (HRP-goat anti-mouse IgG antibody) and incubate at 37℃ on a shaker at 60r / min for 1h. Discard the secondary antibody and wash as above, take 500μL of A solution and B solution in the ECL chemiluminescent substrate colorimetric solution, mix them in equal volumes (prepare and use immediately), add appropriate amount of the above liquids on the membrane, expose and analyze in a gel imaging system to identify the reactivity of the two monoclonal antibodies to LIOmpA (see Figure 6 , Figure 7 ).

[0101] 1.2 IFA specificity analysis of monoclonal antibodies

[0102] McCoy cells that are growing well were cultured at a rate of 1×10 6 1 mL / well was inoculated into a 6-well cell culture plate, and cultured in a 37°C, 5% CO2 cell culture incubator for 12 h; the cell culture medium was discarded, and a 1:10 diluted porcine ileitis live vaccine was inoculated into 3 of the wells, 1 mL / well, and the remaining 3 wells were used as negative controls and cultured in a three-gas incubator for 24 h; the cell supernatant was discarded, and PBS was washed 3 times, 5 min / time, and then 1 mL was added to each well. 4% paraformaldehyde, fix at room temperature for 10 minutes, wash 3 times with PBS, 5 minutes / time; add 500 μL of pre-cooled methanol to each well for 20 minutes at room temperature, wash 3 times with PBS, 5 minutes / time; add 1:200 diluted 12F6 and 5F2 monoclonal antibodies to the corresponding positive and negative control wells, 500 μL / well, incubate at 37℃ for 1 hour, wash as above; add 1:5000 diluted FITC-labeled goat anti-mouse fluorescent secondary antibody, 500 μL / well, incubate at 37℃ for 45 minutes in the dark, wash as above; add 100 μL DAPI staining solution to each well, react at room temperature in the dark for 15 minutes, wash as above; discard DAPI, wash as above, add PBS to cover the bottom of the well for storage; place the cell culture plate in the dark and observe under an inverted fluorescence microscope to identify the IFA reactivity of the two monoclonal antibodies to LI (see Figure 8 , Fig. 9 ).

[0103] 1.3 Analysis of monoclonal antibody stability

[0104] The monoclonal antibodies 5F2 and 12F6 were expanded and passaged for stability analysis. The 1st, 10th, 15th and 20th generation monoclonal antibodies were selected and the antibody titer in the supernatant was determined by indirect ELISA (refer to 1.5 indirect ELISA method antibody detection in Example 1). The results showed that the 5F2 and 12F6 monoclonal antibodies had good stability within the first 20 generations (see Table 3).

[0105] Table 3 Titers of cell culture supernatants of 5F2 and 12F6 monoclonal antibodies at different generations

[0106]

[0107] 1.4 Analysis of monoclonal antibody subtype identification

[0108] The specific steps are as follows:

[0109] (1) Take 10 μL of the supernatant of 12F6 and 5F2 cells, add 990 μL of 1× PBST in a 1.5 mL centrifuge tube, mix well, and add 50 μL to each well of the plate.

[0110] (2) Add goat anti-mouse 1× IgG+IgA+IgM-HRP to the detection plate at a volume of 50 μL / well. Gently tap the plate rack to mix evenly, react at room temperature in the dark for 1 hour, then wash with 1× PBST and dry.

[0111] (3) Add 100 μL of the freshly prepared AB solution and allow to develop color for 15 min in the dark.

[0112] (4) Add 100 μL of stop solution to terminate the reaction.

[0113] (5) OD readings on an ELISA reader 450nm The numerical determination of .

[0114] Subclass identification showed that the subclass of 5F2 positive hybridoma cell line was IgG2b / κ, and the subclass of 12F6 positive hybridoma cell line was IgG1 / κ. Fig.10 .

[0115] 1.5 Analysis of monoclonal antibody antigen binding sites using additive experimental method

[0116] The saturated working concentrations of the two monoclonal antibodies were determined by the multiple dilution method. The determination method is: as the antibody concentration increases, the OD reading of the microplate reader increases. 450nm When the value of remains basically unchanged, the monoclonal antibody dilution is the saturated working concentration; then use the ELISA plate coated with LIOmpA protein, the primary antibody is two different McAbs, each 50 μL, and the steps are the same as the indirect ELISA method in 2.1 of Example 1. Finally, the color development is terminated and the OD is read using an enzyme reader. 450nm, AI = [2A1 + 2 / (A1 + A2) - 1] × 100% can be used to calculate the superposition rate: AI represents the superposition rate, A1 + 2 is the OD of the enzyme-labeled wells after adding the two monoclonal antibodies 450nm Numerical values, A1 and A2 represent the OD of the ELISA wells with only one monoclonal antibody added 450nm The method to determine whether two monoclonal antibodies are directed against the same antigen epitope is to calculate whether the AI ​​value is greater than 50%.

[0117] The AI ​​value of the two monoclonal antibodies was calculated by superposition ELISA, and the value was less than 50%, indicating that the two monoclonal antibodies may target the same antigen epitope (see Table 4).

[0118] Table 4 Antigenic epitope targeting of two monoclonal antibodies

[0119]

[0120] 1.6 Preparation and enzyme labeling of ascites monoclonal antibodies

[0121] 1.6.1 Preparation of ascites

[0122] Select monoclonal antibody 5F2 to immunize mice to prepare ascites. The newly purchased mice need to be fed in the animal room for about a week to avoid stress reactions that lead to mouse death. Before intraperitoneal injection of cells, each mouse needs to be injected with 500 μL of Freund's incomplete adjuvant one week in advance to produce immune stimulation. At this time, the monoclonal antibody cells can be passaged so that they are in the logarithmic growth phase when the mice are immunized. Wash the cells twice with RPMI1640 before injecting the cells, blow off the cells with an elbow pipette, and resuspend them according to the injection of 0.5 mL of cell suspension for each mouse. The cell suspension density is 5×10 6 / mL, and a total of 5 female BALB / c mice aged 5-6 weeks were injected. The mice were observed daily after injection. After about 1-2 weeks, their fur was messy, their abdomen was swollen, and they felt fluctuating when touched. The abdominal cavity can be punctured with a No. 12 needle to collect mouse ascites. Each mouse can be collected 2-3 times. The collected ascites was centrifuged at 1000r / min for 10 minutes, and the supernatant was taken. A portion was packaged for ELISA titer detection, and the rest was stored in a -80℃ refrigerator.

[0123] 1.6.2 Labeling of monoclonal antibody 5F2 Weigh 5 mg of horseradish peroxidase (HRP) and dissolve it in 1 ml of double distilled water. Add 500 μl of freshly prepared NaIO4 and react at 2-8°C for 30 min. The solution will turn grass green. Then add 0.5 ml of ethylene glycol, mix well and react at room temperature in the dark for 30 min. Then add 5 mg of purified 5F2 monoclonal antibody and dialyze in carbonate buffer with pH 9.5 at 2-8°C for 15 h. The next day, add 0.2 ml of freshly prepared NaBH4 to the solution, mix well and react at 2-8°C for 2 h. Then add an equal volume of saturated ammonium sulfate solution, let stand at 2-8°C for 30 min, centrifuge at 7000 r / min for 10 min, discard the supernatant, resuspend in PB, and dialyze in PB at 2-8°C for 1.5 h. Collect the contents of the dialysis bag, adjust the enzyme marker concentration to 4 mg / ml, add an equal volume of glycerol as the enzyme marker stock solution, dispense 1 ml / tube, and store at -70°C or below for future use. Use the purified protein at a concentration of 1 μg / mL to coat the test plate, and the indirect ELISA method to measure the titer of the purified antibody is >1:512000; protein electrophoresis identifies that the antibody has a clear band after purification and a purity of >85%, indicating that the antibody is of high purity. SDS-PAGE results are as follows Fig.11 shown.

[0124] In this example, two hybridoma cell lines were obtained, which the applicant named 5F2 and 12F6. The titers of the primary supernatant after in vitro expansion culture were 1:25600 and 1:51200, respectively.

[0125] The monoclonal antibody 5F2 was identified to have a blocking effect by preliminary tests. After Western blot analysis, it was found that the LI OmpA protein could react specifically with the monoclonal antibody supernatant, but not with SP2 / 0, indicating that the hybridoma cells prepared by the present invention had good specificity. When the 5F2 and 12F6 monoclonal antibodies were continuously passaged in vitro for 20 generations, the antibody titers remained unchanged and the antibodies could be secreted relatively stably. The results of monoclonal antibody subclass identification showed that the monoclonal antibody 5F2 belonged to the IgG2b / κ chain; 12F6 belonged to the IgG1 / κ chain.

[0126] The monoclonal antibody 5F2 was used to immunize mice to prepare ascites, which was then purified and labeled to make an enzyme-labeled monoclonal antibody, providing the necessary conditions for establishing a monoclonal antibody blocking ELISA detection method for Lawsonia intracellularis.

[0127] Example 3: Establishment of ELISA detection method for blocking intracellular Lawsonia spp. monoclonal antibody

[0128] 1.1 Experimental animals and reagents

[0129] 2 healthy Landrace pigs aged 3 months; porcine ileitis live vaccine Ileitis was purchased from Boehringer Ingelheim; enzyme-labeled monoclonal antibody 5F2; ELISA test plate was purchased from Biofil Biotechnology; TMB colorimetric solution was purchased from Solebao Biotechnology; His-tag Purification Resin (reduction-resistant chelating type) and BCA detection kit were purchased from Beyotime Biotechnology; other chemical reagents were domestically produced and of analytical purity.

[0130] The commercial indirect ELISA kit was used to screen the clinical standard negative serum for Lawsonia intracellularis; the prepared porcine polyclonal antibody was used as the standard positive control; and the reference positive serum stored in the laboratory.

[0131] 1.2 Preparation of antigen protein and standard positive serum

[0132] 1.2.1 Preparation of antigen protein

[0133] After the glycerol bacteria stored in the laboratory were revived, they were induced to express LI OmpA protein. The induction effect was identified by SDS-PAGE and then purified. The pure effect was identified by SDS-PAGE again. The purified protein antigen was added with glycerol and protease inhibitors, packaged and frozen in an ultra-low temperature freezer for coating the test plate and preparing standard positive serum. For specific operations, see 1.3 Expression and purification of recombinant protein in Example 1

[0134] 1.2.2 Preparation of standard positive serum

[0135] Before immunization, blood was collected from the anterior vena cava and the negative control serum was separated. Porcine ileitis live vaccine was used for immunization. After dilution according to the instructions, 2 mL of the vaccine was administered intragastrically to each pig for 3 immunizations, with an interval of 3 weeks between each immunization. Blood was collected from the anterior vena cava 7 days after the three immunizations, and the titer was measured using the indirect ELISA test method. If the titer was high, the serum separated from the anterior vena cava was used as the standard positive control.

[0136] 1.3 Preparation of enzyme-labeled monoclonal antibodies

[0137] The ascites prepared by immunizing mice with monoclonal antibody 5F2 cells was purified and HRP labeled, see 1.6 Preparation of monoclonal antibody ascites and enzyme-labeled purification in Example 1.

[0138] 1.4 Blocking ELISA

[0139] The purified LI OmpA protein was coated on a 96-well ELISA plate with 0.05 mol / L carbonate buffer (pH 9.6), 100 μL was added to each well, and incubated overnight at 4°C; the liquid in the plate was shaken off, 300 μL PBST was added to each well, washed 5 times, and patted dry; PBST with 5% BSA was used to block at 37°C for 2h; the liquid in the plate was shaken off, 300 μL PBST was added to each well, washed 5 times, and patted dry; the serum to be tested was added to the ELISA plate, 100 μL per well, and the standard positive and negative pig serum was used as a control, and incubated for 1.5h. The enzyme-labeled monoclonal antibody was diluted 1:20000, 100 μL per well, and incubated for 1h. The liquid in the plate was shaken off, 300 μL PBST was added to each well, washed 5 times, and patted dry; a single-component TMB colorimetric solution was added and reacted for 10min. Finally, 2M sulfuric acid was added to terminate the reaction, and the OD was read using an ELISA reader. 450nm The PI value is calculated by the formula of PI value = (negative serum OD 450nm Value-tested serum OD 450nm value) / negative serum OD 450nm value × 100%.

[0140] 1.5 Selection of optimal reaction conditions for blocking ELISA

[0141] 1.5.1 Screening of the optimal dilution ratio of coated antigen concentration and enzyme-labeled monoclonal antibody

[0142] The square array titration method was used for selection. The purified protein was coated in the ELISA plate with a carbonate coating solution of pH = 9.6 at a concentration of 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 μg / mL, and 0.03125 μg / mL in each column. The LI antibody positive serum and negative serum were respectively coated at 2 0 , 2 1 , 2 2 , 2 3 Perform 4 gradient dilutions and add them to the coated plate in 4 wells per column. Incubate at 37°C for 1.5 h. Follow the blocking ELISA procedure and place the plate into the OD reader. 450nm After reading, the PI value was calculated, and the highest PI value was the subsequent coating antigen concentration and serum dilution (see Table 5).

[0143] Table 5 N / P values ​​of ELISA test in the optimization experiment of antigen coating concentration and serum dilution

[0144]

[0145] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0146] 1.5.2 Optimization of optimal antigen coating conditions

[0147] The subsequent experimental conditions were further optimized based on the optimal antigen coating concentration selected from the above experimental results. Four conditions were set for the experiment at 37°C for 2h, 37°C for 3h, and 37°C for 4h. The subsequent steps were performed according to the blocking ELISA procedure in 1.4 of Example 3. Finally, the OD was read using an ELISA reader. 450nm By calculating the N / P value, the corresponding condition with a large N / P value is selected as the optimal condition (see Table 6).

[0148] Table 6 N / P values ​​detected by ELISA in antigen coating condition experiment

[0149]

[0150]

[0151] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0152] 1.5.3 Optimization of enzyme-labeled monoclonal antibody dilution

[0153] According to the blocking ELISA technique of 1.4 in Example 3, the operation was performed until the primary antibody was incubated, the plate was washed and patted dry, and the enzyme-labeled monoclonal antibody was diluted in 4 gradients of 1:2000, 1:5000, 1:10000 and 1:20000, and the remaining operation steps were continued. By calculating the N / P value, when 1:20000 was the enzyme-labeled monoclonal antibody dilution, the N / P value was 9.60, which was higher than the N / P value corresponding to other enzyme-labeled monoclonal antibody dilutions, so 1:20000 was selected as the optimal enzyme-labeled monoclonal antibody dilution (see Table 7).

[0154] Table 7 N / P values ​​of ELISA detection in the enzyme-labeled monoclonal antibody dilution optimization experiment

[0155]

[0156] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0157] 1.5.4 Selection of blocking solution

[0158] According to the conditions determined by screening the concentration of the coated antigen and the optimal dilution ratio of the serum in 1.5.1 of this example, the ELISA plate was coated and the serum was diluted and incubated at 37°C for 2 hours. After washing with PBST, 5% skim milk, 1% BSA, 2% BSA, and 5% BSA were added to block for 1 hour. Three wells were set for each blocking solution. The subsequent steps were performed according to the blocking ELISA method in 1.4 of Example 3, and the OD was read. 450nm The blocking solution used when the N / P value is the largest is the optimal blocking solution (see Table 8).

[0159] Table 8 N / P value of ELISA detection in blocking solution screening experiment

[0160]

[0161]

[0162] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0163] 1.5.5 Selection of closing conditions

[0164] The detection plate was coated with the blocking solution determined by the above screening. To determine the best blocking conditions, three blocking conditions were used: 37°C for 1 h, 37°C for 2 h, and 37°C for 3 h. The subsequent steps were performed according to the blocking ELISA procedure in 1.4 of Example 3, and the OD was read. 450nm The maximum value of N / P is calculated, and the corresponding closing condition is the optimal closing condition (see Table 9).

[0165] Table 9 N / P values ​​detected by ELISA in the blocking condition optimization experiment

[0166]

[0167] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0168] 1.5.6 Screening of the optimal incubation time for the test serum

[0169] After the ELISA plate was coated and blocked with the determined antigen concentration, the negative and positive sera were added to the plate at the optimal dilution, and incubated at 37°C for 30 min, 37°C for 1 h, and 37°C for 1.5 h, respectively. The subsequent steps were performed according to the blocking ELISA procedure in 1.4 of Example 3, and the OD was read. 450nm The maximum value of N / P is calculated, and the corresponding closing condition is the optimal closing condition (see Table 10).

[0170] Table 10 N / P values ​​of ELISA detection in serum incubation condition optimization experiment

[0171]

[0172] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0173] 1.5.7 Screening of the best enzyme-labeled monoclonal antibody reaction conditions

[0174] After the ELISA plate was coated and blocked with the determined antigen concentration, 100 μL of negative and positive serum were added to each well of the plate. After incubation for 1.5 h, 1:5000 enzyme-labeled monoclonal antibody was added. The plates were incubated at 37°C for 30 min, 37°C for 1 h, and 37°C for 1.5 h, respectively. The subsequent steps were performed according to the blocking ELISA procedure in 1.4 of Example 3, and the OD was read. 450nm The maximum value of N / P was calculated, and the corresponding enzyme-labeled monoclonal antibody action time was the optimal enzyme-labeled monoclonal antibody action time (see Table 11).

[0178] Table 11 ELISA N / P values ​​in the optimization experiment of the best enzyme-labeled monoclonal antibody reaction conditions

[0179]

[0180] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0181] 1.5.8 Screening of the Optimal Action Time of TMB Colorimetric Solution

[0182] To determine the color development time, the coated and sealed ELISA plate was washed and patted dry according to the above-determined conditions. TMB single-component color development solution was added and the color was developed for 5 min, 10 min, 15 min, and 20 min at room temperature in the dark, and then the stop solution was added. The OD was read within 10 min. 450nm The color development time corresponding to the maximum value of N / P is taken as the optimal color development time (see Table 12).

[0183] Table 12 ELISA detection N / P value in the optimal color development time optimization experiment

[0184]

[0185] Note: The conditions corresponding to the bold values ​​are the optimal conditions

[0186] 1.6 Determination of blocking ELISA critical value and result judgment criteria

[0187] 150 clinical serum samples were tested using a commercial indirect ELISA kit and an established ELISA antibody detection method. The test results were plotted into an ROC curve. The area under the ROC curve (AUC) was 0.917, indicating good accuracy. The Youden index was calculated using the curve coordinates. The cut-off point was a blocking rate of 29.5%, corresponding to the maximum value of the Youden index of 0.757. When the blocking rate of 29.5% was used as the critical value, the corresponding sensitivity was 0.857 and the specificity was 0.90. Both the sensitivity and specificity were good. To facilitate calculations, the criteria were determined as follows: PI values ​​≥ 30% were considered positive, and PI values ​​< 30% were considered negative (see Fig.12 , Table 13, Table 14).

[0188] Table 13 ROC curve analysis

[0189]

[0190] Table 14 Analysis of ROC curve coordinates

[0191]

[0192]

[0193]

[0194] 1.7 Repeatability test

[0195] 1.7.1 Intra-batch replicate testing

[0196] The protein coated on the control ELISA strips was purified from the same batch. After the optimal conditions were coated and blocked, a total of 8 clinically negative, weakly positive and strongly positive sera were selected. Each serum was repeated 3 times to calculate the blocking rate. The coefficient of variation CV was calculated based on the PI value, which showed whether the intra-batch repeatability was good. The coefficient of variation of the blocking rate of 3 repeated sera in the batch was less than 10%, indicating that the intra-batch coefficient of variation was good (see Table 15).

[0197] Table 15 Intra-batch repeat tests

[0198]

[0199] 1.7.2 Repeated testing between batches

[0200] The antigen coated on the ELISA strips was a protein purified from three batches at different times. After being coated and blocked under the optimal conditions, a total of 8 negative, weakly positive and strongly positive sera were screened clinically and the blocking rate was calculated after three repeated experiments. The coefficient of variation CV was calculated based on the PI value, from which it can be seen whether the batch reproducibility of this method is good. The coefficient of variation of the blocking rate of three repeated sera between batches was less than 15%, indicating that the batch variation coefficient was good (see Table 16).

[0201] Table 16 Batch Repeat Test

[0202]

[0203]

[0204] 1.8 Sensitivity test of blocking ELISA

[0205] According to the optimal experimental conditions, the positive serum of Lawsonia intracellularis was selected from 2 0 Dilute to 2 4 The established blocking ELISA method was used to detect the OD450nm value of the corresponding serum dilution and calculate the blocking rate. The results showed that at a serum dilution of 2 3 The blocking rate was 48.13%, which was determined to be positive. Therefore, this method can detect up to 8-fold dilution (see Table 17).

[0206] Table 17 Sensitivity test of blocking ELISA

[0207]

[0208] 1.9 Specificity test of blocking ELISA

[0209] The sera of swine fever virus (CSFV), porcine blue ear virus (PRRSV), porcine epidemic diarrhea virus (PEDV), foot-and-mouth disease virus (FMDV), pseudorabies virus (PRV), porcine circovirus type Ⅰ (PCV-Ⅰ), Pasteurella multocida (PM), positive serum, Actinobacillus pleuropneumoniae (APx), Escherichia coli (E.coil), and type Ⅱ Streptococcus suis (SS-2) stored in the laboratory were taken, and the OD450nm value of the corresponding serum dilution was detected by the established blocking ELISA method and the blocking rate was calculated. The blocking ELISA test results showed that the blocking rates of the positive sera of the antibodies to pathogens were <30% except for the positive serum of the antibodies to Lawsonia intracellularis (see Table 18).

[0210] Table 18 Specificity test of blocking ELISA

[0211]

[0212]

[0213] 1.10 Comparison between blocking ELISA and commercial ELISA

[0214] 150 clinical sera were tested simultaneously using a commercial indirect ELISA test kit and the blocking ELISA method established by the present invention. The results of the blocking ELISA method established by the present invention were determined by referring to the determination of the blocking ELISA critical value and the result standard determination in Example 1.6 of this embodiment, and compared with the commercial indirect ELISA test results, and the compliance rate was calculated (see Table 19).

[0215] Table 19 Conformity of samples detected by blocking ELISA and commercial ELISA

[0216]

[0217] The above description is only a specific implementation of the present invention, but the protection scope of the present invention is not limited thereto. Any person familiar with the technology can understand and think of any changes or substitutions within the technical scope disclosed by the present invention, which should be included in the scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A method for preparing a monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis, characterized in that: The monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis is produced by hybridoma cell line 5F2, and the deposit number of the hybridoma cell line 5F2 is CCTCCNO: C2023263.

2. The hybridoma cell line according to claim 1, characterized in that The encoding nucleotide sequence of the Lawsonia intracellularis outer membrane protein OmpA is shown in SEQ ID NO:1, and the encoding amino acid sequence of the Lawsonia intracellularis outer membrane protein OmpA is shown in SEQ ID NO:

2.

3. Monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis, characterized in that: The Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody can be used for immunological detection of the Lawsonia intracellularis outer membrane protein OmpA.

4. The monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis according to claim 3, characterized in that: The Lawsonia intracellularis outer membrane protein OmpA monoclonal antibody can be used for detecting the Lawsonia intracellularis outer membrane protein OmpA in ELISA, WB or IFA experiments.

5. An antibody preparation, comprising the monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis according to claim 1, or comprising a nucleotide fragment of the monoclonal antibody.

6. The antibody preparation according to claim 4, characterized in that: The antibody preparation is useful for the effective diagnosis or detection of Lawsonia intracellularis for non-diagnostic purposes.

7. Use of the monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis according to claim 1 in detecting antibodies against Lawsonia intracellularis by blocking ELISA for non-diagnostic purposes.

8. Use of the monoclonal antibody against the outer membrane protein OmpA of Lawsonia intracellularis according to claim 1 in the preparation of a kit for diagnosis or detection of Lawsonia intracellularis for non-diagnostic purposes.

Citation Information

Patent Citations

  • ELISA (Enzyme Linked Immunosorbent Assay) kit for detecting lawsonia intracellularis antibody

    CN103698514A

  • Enzyme-linked immunosorbent assay (ELISA) test kit for testing lawsonia intracellularis (LI) of pigs

    CN107576791A

  • Recombinant vaccine against proliferative enteropathy in animals

    CN111655282A

  • Swine-derived Lawsonia intracellularis Omp2 protein monoclonal antibody and application thereof

    CN113292651A

  • ELISA (enzyme-linked immunosorbent assay) detection kit and method for lawsonia intracellularis antibody

    CN118112239A